勘误：C反应蛋白异构体作为新冠病毒疾病严重程度的预后标志物
Corrigendum: C-reactive protein isoforms as prognostic markers of COVID-19 severity.
作者信息
Molins Blanca, Figueras-Roca Marc, Valero Oliver, Llorens Victor, Romero-Vázquez Sara, Sibila Oriol, Adan Alfredo, Garcia-Vidal Carolina, Soriano Alex
机构信息
Group of Ocular Inflammation: Clinical and Experimental Studies, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Institut Clínic d'Oftalmologia (ICOF), Hospital Clínic, Barcelona, Spain.
出版信息
Front Immunol. 2024 Jun 21;15:1447976. doi: 10.3389/fimmu.2024.1447976. eCollection 2024.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2022.1105343.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fimmu.2022.1105343。]
相似文献
1
Corrigendum: C-reactive protein isoforms as prognostic markers of COVID-19 severity.勘误：C反应蛋白异构体作为新冠病毒疾病严重程度的预后标志物
Front Immunol. 2024 Jun 21;15:1447976. doi: 10.3389/fimmu.2024.1447976. eCollection 2024.
2
Corrigendum: Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients.勘误：重症 COVID-19 患者肠道通透性破坏的血浆标志物
Front Immunol. 2021 Oct 4;12:779064. doi: 10.3389/fimmu.2021.779064. eCollection 2021.
3
Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.勘误：尿激酶型纤溶酶原激活剂与纤溶酶原激活剂抑制剂-1复合物作为新型冠状病毒肺炎的血清生物标志物
Front Immunol. 2024 Mar 13;15:1390698. doi: 10.3389/fimmu.2024.1390698. eCollection 2024.
4
Corrigendum: Definition of the immune parameters related to COVID-19 severity.勘误：与COVID-19严重程度相关的免疫参数的定义。
Front Immunol. 2023 May 24;14:1219179. doi: 10.3389/fimmu.2023.1219179. eCollection 2023.
5
Corrigendum: Monomeric C-Reactive Protein Binds and Neutralizes Receptor Activator of NF-κB Ligand-Induced Osteoclast Differentiation.勘误：单体C反应蛋白结合并中和核因子κB受体激活剂配体诱导的破骨细胞分化
Front Immunol. 2020 Nov 24;11:619847. doi: 10.3389/fimmu.2020.619847. eCollection 2020.
6
Corrigendum: TACI Isoforms Regulate Ligand Binding and Receptor Function.勘误：跨膜激活剂和钙调亲环素配体相互作用分子（TACI）异构体调节配体结合和受体功能。
Front Immunol. 2019 Dec 3;10:2772. doi: 10.3389/fimmu.2019.02772. eCollection 2019.
7
Corrigendum: Epigenetic immune monitoring for COVID-19 disease course prognosis.勘误：用于COVID-19病程预后的表观遗传免疫监测。
Front Immunol. 2024 Jun 27;15:1451571. doi: 10.3389/fimmu.2024.1451571. eCollection 2024.
8
Corrigendum: Interferon-α2b Treatment for COVID-19.勘误：α-2b干扰素治疗2019冠状病毒病
Front Immunol. 2020 Oct 27;11:615275. doi: 10.3389/fimmu.2020.615275. eCollection 2020.
9
C-reactive protein isoforms as prognostic markers of COVID-19 severity.C 反应蛋白异构体作为 COVID-19 严重程度的预后标志物。
Front Immunol. 2023 Jan 18;13:1105343. doi: 10.3389/fimmu.2022.1105343. eCollection 2022.
10
Corrigendum: Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity.勘误：根据疾病严重程度，新冠病毒感染后1年的不同免疫反应。
Front Immunol. 2022 May 24;13:929770. doi: 10.3389/fimmu.2022.929770. eCollection 2022.
Zotero 插件